Can a GLP-1 reverse prediabetes?

Dr. Linda's take

"Reverse" is the word everyone reaches for, and it is worth slowing down on, because the honest answer sits in the gap between what these medications do while you take them and what happens after you stop.

The short version: while you are on treatment, the evidence that these medications lower the odds of crossing into type 2 diabetes is strong, and in one three-year trial it was dramatic. But the best data we have on stopping suggest that normal glucose levels largely drift back. That makes "reverse" the wrong mental model, and "hold back, as long as treatment continues" the closer one.

That distinction is not a technicality. It changes what you plan for. This is general education, not a recommendation for any individual.

What is prediabetes, exactly?

Prediabetes means blood glucose levels that are higher than normal, but not high enough to be diagnosed as type 2 diabetes. It is a threshold on a continuum rather than a separate disease.

It is also not harmless while you wait. A meta-analysis in the BMJ pooling 129 studies and more than 10 million people found that prediabetes was associated with an increased risk of all-cause mortality, composite cardiovascular disease, coronary heart disease, and stroke compared with normal glucose levels. The relative increases were modest in size, but they were consistent.

And without intervention, it tends to move in one direction. People with prediabetes have a high chance of developing type 2 diabetes within five to ten years.

What already worked before these medications existed?

Worth knowing, because it is the benchmark everything else is measured against, and because it is not a drug.

In the Diabetes Prevention Program, a randomized trial of 3,234 adults at high risk, a structured lifestyle intervention reduced the incidence of type 2 diabetes by 58% compared with placebo, and metformin reduced it by 31%. Lifestyle beat the medication, and it beat it decisively.

That result is more than twenty years old and it still stands. Any conversation about newer medications that skips it is selling something.

Do GLP-1 medications lower the odds of developing type 2 diabetes?

Yes, and for tirzepatide the effect size is the largest in this literature.

In SURMOUNT-1, a phase 3 randomized trial of 2,539 adults with obesity or overweight and prediabetes, participants were treated for 176 weeks, which is about three years. Type 2 diabetes was diagnosed in 1.3% of participants receiving tirzepatide compared with 13.3% receiving placebo. The investigators concluded that three years of tirzepatide in people with obesity and prediabetes produced substantial and sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than placebo.

There is also older, longer evidence for a different medication in this class. In a three-year randomized, double-blind trial of liraglutide 3.0 mg in people with prediabetes, 2% of the liraglutide group versus 6% of the placebo group were diagnosed with diabetes, and the time to onset of diabetes was 2.7 times longer with liraglutide than with placebo.

For semaglutide, the picture is thinner than most people assume. Among STEP 1 participants who had prediabetes at baseline, more reverted to normal glucose levels at week 68 on semaglutide than on placebo, 93.6% versus 41.5%. That is a striking number, but note what it measures: a shift in glycemic status, not a diabetes-prevention endpoint of the kind SURMOUNT-1 and the liraglutide trial were built to test.

So can it actually reverse prediabetes?

This is the section I would ask you to read twice, because it is where the marketing and the evidence part ways.

Look at what happened when people stopped. In the STEP 1 trial extension, participants who came off semaglutide regained on average 11.6 percentage points of the body weight they had lost by week 120, and the cardiometabolic improvements seen during treatment reverted towards baseline for most variables. On the specific question of glucose: reversion to normal glucose levels, which had reached 93.6% on semaglutide at week 68, was down to 43.3% at week 120 after withdrawal, versus 34.0% in the placebo arm.

Read those two numbers next to each other. Normoglycemia on treatment, 93.6%. Normoglycemia a year after stopping, 43.3%. Most of the glycemic benefit went with the medication.

The tirzepatide data point the same way, even over a short window. After just 17 weeks off treatment, type 2 diabetes had been diagnosed in 2.4% of those who had received tirzepatide versus 13.7% of those on placebo. The gap versus placebo held, which is genuinely good news, but the rate in the tirzepatide group nearly doubled from 1.3% in only 17 weeks off the drug, and there is no long off-treatment follow-up.

And in SURMOUNT-4, a randomized withdrawal trial, people who continued tirzepatide lost a further 5.5% of body weight between weeks 36 and 88, while those switched to placebo regained 14.0%.

So: these medications substantially reduce progression to type 2 diabetes while they are being taken, and many people with prediabetes do return to normal glucose levels on treatment. What the evidence does not support is the idea that a course of treatment durably reverses prediabetes once the medication stops. Metabolic disease behaves like a chronic condition here, because that is what it is.

Is any GLP-1 approved for prediabetes?

No. We read the current prescribing information for Zepbound, Wegovy, and Saxenda, and none of them carries an indication for prediabetes or for reducing progression to type 2 diabetes. Their indications are for weight reduction, and in some cases for cardiovascular risk, obstructive sleep apnea, or liver disease.

That is worth sitting with for a moment. Saxenda is the very drug with the three-year prediabetes prevention trial described above, and its label still contains no prediabetes indication. Using any of these medications specifically to prevent diabetes is therefore off-label, which is a conversation to have explicitly with a clinician rather than an obstacle in itself.

What should you ask your clinician?

If you want a structured way into that conversation, Body Good Studio's quiz maps your symptoms to a starting point before you speak with a clinician.

Frequently asked questions

Can a GLP-1 reverse prediabetes permanently?

The evidence does not support that. Normal glucose levels are commonly restored during treatment, but in the STEP 1 trial extension the share of people with normal glucose fell from 93.6% at week 68 on semaglutide to 43.3% a year after withdrawal. The better framing is that these medications hold progression back while they are taken.

How much do these medications reduce the risk of type 2 diabetes?

In SURMOUNT-1, over about three years, type 2 diabetes was diagnosed in 1.3% of the tirzepatide group versus 13.3% of the placebo group. In a three-year liraglutide trial, 2% of the liraglutide group versus 6% of the placebo group were diagnosed with diabetes.

Is lifestyle change still worth it if medication works?

Yes. In the Diabetes Prevention Program, a structured lifestyle intervention reduced the incidence of type 2 diabetes by 58%, compared with 31% for metformin. It remains the benchmark, not a consolation prize.

Is any GLP-1 FDA-approved to treat prediabetes?

No. The current Zepbound, Wegovy, and Saxenda labels carry no indication for prediabetes or diabetes prevention. Use for that purpose is off-label.

Does prediabetes cause harm even if it never becomes diabetes?

A BMJ meta-analysis of 129 studies found prediabetes was associated with a modestly increased risk of all-cause mortality, cardiovascular disease, coronary heart disease, and stroke, compared with normal glucose levels.

References

1. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2026). Prediabetes & Insulin Resistance. National Institutes of Health. https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/prediabetes-insulin-resistance (Accessed 2026-07-14).
2. Cai X, Zhang Y, Li M, et al. (2020). Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC7362233/ (Accessed 2026-07-14).
3. Diabetes Prevention Program Research Group (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC1370926/ (Accessed 2026-07-14).
4. Jastreboff AM, le Roux CW, Stefanski A, et al. (2025). Tirzepatide for obesity treatment and diabetes prevention (SURMOUNT-1, 176 weeks). New England Journal of Medicine, via PubMed (National Library of Medicine). https://pubmed.ncbi.nlm.nih.gov/39536238/ (Accessed 2026-07-14).
5. le Roux CW, Astrup A, Fujioka K, et al. (2017). 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. The Lancet, via PubMed (National Library of Medicine). https://pubmed.ncbi.nlm.nih.gov/28237263/ (Accessed 2026-07-14).
6. Wilding JPH, Batterham RL, Davies M, et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC9542252/ (Accessed 2026-07-14).
7. Aronne LJ, Sattar N, Horn DB, et al. (2024). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC10714284/ (Accessed 2026-07-14).
8. Eli Lilly and Company / U.S. Food and Drug Administration (2026). ZEPBOUND (tirzepatide) injection - Prescribing Information. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b (Accessed 2026-07-14).
9. Novo Nordisk / U.S. Food and Drug Administration (2026). WEGOVY (semaglutide) - Prescribing Information. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b (Accessed 2026-07-14).
10. Novo Nordisk / U.S. Food and Drug Administration (2026). SAXENDA (liraglutide) injection - Prescribing Information. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143 (Accessed 2026-07-14).